{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:00:46Z","timestamp":1789585246116,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>X-linked hypophosphatemic rickets (XLH) is associated with uninhibited FGF23 activity, which leads to phosphaturia, hypophosphatemia and depressed active vitamin D (1,25OH2D) levels. Conventional treatment with phosphate supplements and vitamin D analogs may lead to hypercalciuria (HC), nephrocalcinosis (NC) and hyperparathyroidism. We investigated the effects of burosumab treatment, an anti-FGF23 monoclonal antibody recently approved for XLH, on these complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study included children with XLH who were treated with burosumab for at least one year at one of three referral centers. Clinical and biochemical potential treatment outcomes were regularly followed, including multiple urine calcium measurements and NC severity score (0\u2009=\u2009no NC, 3\u2009=\u2009worse NC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-six (13 male) children aged 7.6\u2009\u00b1\u20093.9 years were followed for 27.5\u2009\u00b1\u20099.6 months. Mean serum phosphate levels rapidly increased from 2.67\u2009\u00b1\u20090.61 at baseline to 3.57\u2009\u00b1\u20090.53\u2005mg\/dL after 3 months (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001) and remained stable thereafter. Concomitant decreases were observed in phosphaturia, serum alkaline phosphatase and parathyroid hormone. HC (U-Ca\/Cr\u2009&amp;gt;\u20090.2\u2005mg\/mg) was detected in 2\/26 (7.7%) patients before burosumab initiation, resolved in one and persisted, albeit improved, in the second. Two patients were newly diagnosed with HC, 15 and 3 months after therapy, which persisted in one of them despite dose reduction attempts. Seven patients had NC at baseline (mean score: 1.8\u2009\u00b1\u20090.34), but none showed deterioration or developed new NC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In children with XLH treated with burosumab, HC was an infrequent side effect and preexisting NC did not worsen.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2024.1487890","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T04:23:12Z","timestamp":1733113392000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Nephrocalcinosis tendency does not worsen under burosumab treatment for X-linked hypophosphatemic rickets: a multicenter pediatric study"],"prefix":"10.3389","volume":"12","author":[{"given":"Shelly","family":"Levi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Davidovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Shapira Rootman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avivit","family":"Brener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Gal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Borovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Cleper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Lebenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Levy-Shraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dov","family":"Tiosano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Chezana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravit","family":"Regev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Zeitlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in southern Denmark","volume":"160","author":"Beck-Nielsen","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00431-010-1382-5","article-title":"Clinical practice. Fibroblast growth factor (FGF)23: a new hormone","volume":"170","author":"Alon","year":"2011","journal-title":"Eur J Pediatr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrendo.2009.196","article-title":"The FGF23-klotho axis: endocrine regulation of phosphate homeostasis","volume":"5","author":"Razzaque","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1074\/jbc.M207872200","article-title":"Human fibroblast growth factor-23 mutants suppress na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production","volume":"278","author":"Saito","year":"2003","journal-title":"J Biol Chem"},{"key":"B7","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect"},{"key":"B8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12325-019-01170-7","article-title":"Complications of phosphate and vitamin D treatment in X-linked hypophosphataemia","volume":"37","author":"Arango Sancho","year":"2020","journal-title":"Adv Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1530\/EC-20-0291","article-title":"Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations","volume":"9","author":"Padidela","year":"2020","journal-title":"Endocr Connect"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1007\/s00431-023-05190-y","article-title":"Linear growth of children with X-linked hypophosphatemia treated with burosumab: a real-life observational study","volume":"182","author":"Levy-Shraga","year":"2023","journal-title":"Eur J Pediatr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/s41430-020-0558-y","article-title":"Vitamin D deficiency 2.0: an update on the current status worldwide","volume":"74","author":"Amrein","year":"2020","journal-title":"Eur J Clin Nutr"},{"key":"B16","first-page":"1","article-title":"2000 CDC growth charts for the United States: methods and development","author":"Kuczmarski","year":"2002","journal-title":"Vital Health Stat 11"},{"key":"B17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2223\/JPED.826","article-title":"Urinary excretion of calcium, uric acid and citrate in healthy children and adolescents","volume":"78","author":"Penido","year":"2002","journal-title":"J Pediatr (Rio J)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s00431-020-03662-z","article-title":"Spot urine samples to estimate 24-hour urinary calcium excretion in school-age children","volume":"179","author":"Paccaud","year":"2020","journal-title":"Eur J Pediatr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0031-3955(16)36251-4","article-title":"The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents","volume":"34","author":"Schwartz","year":"1987","journal-title":"Pediatr Clin North Am"},{"key":"B20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/tropej\/46.3.132","article-title":"Radiographic scoring method for the assessment of the severity of nutritional rickets","volume":"46","author":"Thacher","year":"2000","journal-title":"J Trop Pediatr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s002470050539","article-title":"Observer reliability in grading nephrocalcinosis on ultrasound examinations in children","volume":"29","author":"Dick","year":"1999","journal-title":"Pediatr Radiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"20420188211001150","DOI":"10.1177\/20420188211001150","article-title":"Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy","volume":"12","author":"Brener","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"947814","DOI":"10.3389\/fendo.2022.947814","article-title":"Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy","volume":"13","author":"Brener","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fendo.2020.00338","article-title":"Clinical evidence for the benefits of burosumab therapy for X-linked hypophosphatemia (XLH) and other conditions in adults and children","volume":"11","author":"Schindeler","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00467-013-2466-z","article-title":"Hypophosphatemic rickets due to perturbations in renal tubular function","volume":"29","author":"Penido","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev.med.051308.111339","article-title":"Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23","volume":"61","author":"Bergwitz","year":"2010","journal-title":"Annu Rev Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1007\/s00467-010-1565-3","article-title":"FGF23 and the parathyroid glands","volume":"25","author":"Silver","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","article-title":"Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23","volume":"100","author":"Imel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s00467-022-05484-7","article-title":"Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets","volume":"37","author":"Paloian","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1430921","DOI":"10.3389\/fped.2024.1430921","article-title":"X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteristics of a single-center pediatric cohort in North America before and after burosumab","volume":"12","author":"Paloian","year":"2024","journal-title":"Front Pediatr"},{"key":"B33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0022-3476(97)70162-8","article-title":"Urinary phosphate\/creatinine, calcium\/creatinine, and magnesium\/creatinine ratios in a healthy pediatric population","volume":"131","author":"Matos","year":"1997","journal-title":"J Pediatr"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1093\/ndt\/gfp115","article-title":"Nephrocalcinosis: new insights into mechanisms and consequences","volume":"24","author":"Vervaet","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B35","doi-asserted-by":"publisher","first-page":"101227","DOI":"10.1016\/j.eclinm.2021.101227","article-title":"Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: a pragmatic, prospective, randomised, open, blinded endpoint (PROBE) trial","volume":"43","author":"Ruggenenti","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e998","DOI":"10.1210\/clinem\/dgad223","article-title":"Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia","volume":"108","author":"Ewert","year":"2023","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1487890\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T04:23:15Z","timestamp":1733113395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1487890\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":36,"alternative-id":["10.3389\/fped.2024.1487890"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1487890","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"article-number":"1487890"}}